Overview

Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

Status:
Active, not recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

This study aims to determine if treatment with apixaban, compared with aspirin, will reduce the risk of ischemic stroke and systemic embolism in patients with device-detected sub-clinical atrial fibrillation and additional risk factors for stroke.

Phase:

Phase 4

Details

Lead Sponsor:

Population Health Research Institute

Collaborators:

Bristol-Myers Squibb
Canadian Institutes of Health Research (CIHR)
Medtronic
Pfizer

Treatments:

Apixaban
Aspirin